ACIU — AC Immune SA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1651625 ·
Last close
$2.61
Market Cap
$259.50M
52W High
$4.00
52W Low
$2.10
ADV30
186,349
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 15,113,000 | — | 1,193,000 | 1,874,000 | 150,401,000 | 27,757,000 | 115,232,000 |
| Mar 2026 | 1,119,000 | — | -14,788,000 | -14,801,000 | 137,421,000 | 19,169,000 | 105,887,000 |
| Dec 2025 | 338,000 | — | -14,406,000 | -14,373,000 | 154,251,000 | 26,795,000 | 109,367,000 |
| Sep 2025 | 939,000 | — | -15,699,000 | -15,858,000 | 171,607,000 | 27,741,000 | 109,163,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,262,000
Investing CF
$63,542,000
Financing CF
$-1,020,000
CapEx
$-900,000
Dividends Paid
—
Buybacks
$-5,000
EPS Diluted TTM
$-0.71
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-450,440,000
Inventory
—
Receivables
$13,645,000
ST Investments
$47,600,000
EBIT TTM
$-42,944,000
Pretax Income TTM
$-43,158,000
Interest Exp TTM
$214,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,509,000
EBITDA
$-42,479,000
Free Cash Flow
$-33,138,624
Enterprise Value
$203,163,328
Total Cash
$75,357,000
Total Debt
$4,102,000
Shares Out
99,426,932
Trailing EPS
$-0.53
Book Value
$0.44
ROE
-78.5%
ROA
-16.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,573,000 | -68,863,000 | -70,447,000 | 154,251,000 | 109,367,000 | 44,884,000 | -69,262,000 |
| Dec 2024 | 27,309,000 | -52,378,000 | -50,916,000 | 230,913,000 | 118,643,000 | 112,270,000 | 65,842,000 |
| Dec 2023 | 14,801,000 | -53,624,000 | -54,233,000 | 182,814,000 | 22,171,000 | 160,643,000 | -60,408,000 |
| Dec 2022 | 3,935,000 | -70,847,000 | -70,753,000 | 185,938,000 | 16,947,000 | 168,991,000 | -73,568,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.60
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.61 · call volume: 36 · put volume: 225
Expected Move to 2027-02-19:
±$1.10
(42.15%) —
implied range
$1.51 –
$3.71
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGNX | MACROGENICS INC | $258.62M | $4.06 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $263.52M | $0.15 | — |
| PRLD | Prelude Therapeutics Inc | $254.44M | $3.91 | — |
| IFRX | InflaRx N.V. | $268.21M | $1.82 | — |
| IMRX | Immuneering Corp | $269.14M | $4.16 | — |
News headlines (Yahoo Finance, 1h cache)
AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals
2026-09-26 20:02 · Yahoo
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
2026-09-28 15:04 · Yahoo
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
2026-09-28 14:45 · Yahoo
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
2026-09-28 14:03 · Yahoo
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
2026-09-25 15:02 · Yahoo
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
2026-09-25 14:28 · Yahoo
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
2026-09-24 15:50 · Yahoo
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
2026-09-24 13:35 · Yahoo
CBAK Energy Technology Stock And 2 Top Penny Stocks To Watch
2026-09-23 17:16 · Yahoo
Vertex Posts Positive Phase II Data on Kidney Disease Drug
2026-09-23 16:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.